Bulgaria vs Jordan: Average cost of multi drug-resistant tuberculosis treatment
Bulgaria
6,271 constant 2022 US$
in 2024
Jordan
5,124 constant 2022 US$
in 2024
Bulgaria rank
6th
Jordan rank
8th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bulgaria
- Jordan
How they compare
Bulgaria currently reports 6,271 constant 2022 US$ against 5,124 constant 2022 US$ in Jordan, a difference of 1,147 constant 2022 US$.
That makes Bulgaria's figure about 1.2 times Jordan's.
The two have swapped places 3 times across 7 shared years of data; in 2018 it was Jordan ahead.
Bulgaria ranks 6th and Jordan ranks 8th of 92 countries.
Across the 2 decades both report, Bulgaria averaged higher in 1 and Jordan in 1.
Head to head by decade
| Decade | Bulgaria | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,490 constant 2022 US$ | 17,875 constant 2022 US$ | 15,385 constant 2022 US$ | Jordan |
| 2020s | 4,840 constant 2022 US$ | 3,905 constant 2022 US$ | 935 constant 2022 US$ | Bulgaria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bulgaria or Jordan?
- Bulgaria, at 6,271 constant 2022 US$ against 5,124 constant 2022 US$ in Jordan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bulgaria and Jordan?
- 1,147 constant 2022 US$, with Bulgaria ahead.
- How many years of comparable data are there for Bulgaria and Jordan?
- 7 years are reported by both, from 2018 to 2024.
- How do Bulgaria and Jordan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bulgaria ranks 6th and Jordan ranks 8th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.